CA
NZ
UK
AU
IND
US
…
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Conduit Pharmaceuticals Inc. (NASDAQ: CDT) are limited, and the company appears to be an early-stage pharmaceuticals/biotech issuer with few publicly detailed operations. Long-term growth may depend on clinical trial progress, regulatory milestones, licensing or partnerships and successful commercialization of any product candidates, which could support upside if development milestones are achieved.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 266.87M | -17.80M | 2.84M | -4.89M | -3.66M |
| Net income | 237.52M | -17.80M | -0.54M | -4.89M | -3.66M |
| Selling general administrative | 533.37M | 12.04M | 5.17M | 3.05M | 2.89M |
| Gross profit | 1031.17M | -0.46M | - | - | - |
| Reconciled depreciation | 2.42M | 0.46M | 0.00M | - | - |
| Ebit | 318.16M | -16.30M | -0.32M | -3.16M | -3.17M |
| Ebitda | 371.52M | -15.84M | 3.05M | -1.43M | -2.69M |
| Depreciation and amortization | 53.36M | 0.46M | 0.17M | 1.73M | 0.48M |
| Operating income | 315.69M | -15.42M | -5.26M | -3.16M | -3.17M |
| Other operating expenses | 2399.50M | 15.42M | 5.26M | 3.16M | 3.17M |
| Interest expense | 46.35M | 1.51M | 0.21M | - | - |
| Interest income | 0.03M | 0.01M | 0.03M | - | - |
| Net interest income | -0.29M | -1.49M | -0.39M | - | - |
| Income tax expense | 29.34M | -29.53M | -0.17M | - | - |
| Total revenue | 2715.19M | 922.22M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 715.48M | 14.96M | 5.26M | 3.16M | 3.17M |
| Cost of revenue | 1684.02M | 0.46M | - | - | - |
| Total other income expense net | -48.83M | -2.38M | 8.10M | -1.73M | -0.48M |
| Net income from continuing ops | -39.22M | -17.81M | -0.54M | -4.89M | -3.66M |
| Net income applicable to common shares | - | - | - | -4.89M | -3.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 3543.62M | 4.19M | 7.22M | 0.01M | 0.00M |
| Intangible assets | 399.80M | 419.07M | - | 0.01M | - |
| Other current assets | 94.30M | 1.67M | 1.50M | - | - |
| Total liab | 2279.20M | 10.99M | 7.68M | 10.08M | 5.94M |
| Total stockholder equity | 1264.42M | -6.79M | -0.46M | -10.08M | -5.94M |
| Deferred long term liab | - | - | - | 0.01M | - |
| Other current liab | 336.07M | 1.96M | 0.60M | 3.99M | 2.23M |
| Common stock | 0.50M | 0.01M | 0.01M | - | - |
| Capital stock | 0.00M | 0.01M | 0.01M | 0.00M | 0.00M |
| Retained earnings | 1405.57M | -29.10M | -11.30M | -10.76M | -5.88M |
| Other liab | - | - | - | 4.08M | 2.96M |
| Good will | 1036.82M | 1018.68M | - | - | - |
| Other assets | - | - | - | 0.01M | - |
| Cash | 389.89M | 0.55M | 4.23M | - | - |
| Total current liabilities | 697.50M | 10.74M | 1.80M | 3.99M | 2.23M |
| Net debt | 895.78M | 6.90M | -3.24M | 2.01M | 0.75M |
| Short term debt | - | 7.35M | 0.98M | - | - |
| Short long term debt | 0.66M | 7.23M | 0.98M | - | - |
| Short long term debt total | 1285.67M | 7.46M | 0.98M | 2.01M | 0.75M |
| Other stockholder equity | -44.45M | 21.88M | 10.42M | 0.69M | -0.07M |
| Total current assets | 1349.38M | 2.71M | 5.73M | - | - |
| Net tangible assets | - | - | - | -10.08M | -5.94M |
| Short term investments | - | 369.75M | - | - | - |
| Net receivables | 462.85M | 0.49M | - | - | - |
| Long term debt | - | - | - | 2.01M | 0.75M |
| Inventory | 402.35M | 343.10M | - | - | - |
| Accounts payable | 361.43M | 1.43M | 0.21M | - | - |
| Accumulated other comprehensive income | -97.20M | 0.41M | 0.41M | 0.69M | -0.07M |
| Non currrent assets other | 177.09M | -1436.58M | 1.49M | - | - |
| Non current assets total | 2194.24M | 1.48M | 1.49M | 0.01M | 0.00M |
| Capital lease obligations | 0.12M | 0.23M | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -0.04M | 0.72M | -0.18M | 0.00M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -128.24M | -0.04M | 0.72M | -0.18M | -0.18M |
| Net borrowings | -2.17M | 2.45M | 2.29M | 1.11M | 0.69M |
| Total cash from financing activities | -217.77M | 6.07M | 10.93M | 2.45M | 1.90M |
| Change to operating activities | - | - | - | 0.60M | 1.36M |
| Net income | 237.52M | -17.80M | -0.54M | -4.89M | -3.66M |
| Change in cash | 19.59M | -3.67M | 4.23M | 0.00M | -0.25M |
| Begin period cash flow | 370.30M | 4.23M | 0.35M | 0.00M | 0.25M |
| End period cash flow | 389.89M | 0.55M | 4.23M | 0.00M | 0.00M |
| Total cash from operating activities | 354.86M | -9.68M | -7.72M | -2.27M | -2.15M |
| Issuance of capital stock | 19.70M | 3.33M | 0.00M | 1.34M | 1.21M |
| Depreciation | 129.43M | 0.46M | 0.00M | - | - |
| Other cashflows from investing activities | 0.19M | -0.71M | 0.23M | -0.18M | -0.18M |
| Dividends paid | 7.97M | 8.20M | - | - | - |
| Change to inventory | -48.23M | 24.32M | - | - | - |
| Change to account receivables | -37.77M | 18.86M | - | - | - |
| Sale purchase of stock | -0.11M | 0.00M | - | - | - |
| Other cashflows from financing activities | -227.23M | 0.29M | 8.64M | 1.11M | 0.69M |
| Change to netincome | - | - | - | 2.02M | 0.15M |
| Capital expenditures | 136.17M | 0.05M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 4.73M | -0.14M | -2.52M | 0.93M | 1.36M |
| Stock based compensation | 30.02M | 1.63M | 0.20M | - | - |
| Other non cash items | -51.86M | 6.17M | -4.87M | 1.69M | 0.15M |
| Free cash flow | 218.69M | -9.73M | -7.72M | -2.27M | -2.15M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| CDT Conduit Pharmaceuticals Inc. |
-0.01 12.73% |
0.07 | - | - | - | 5.16 | -55.41 |
| NVO Novo Nordisk A/S |
0.75 1.92% |
39.89 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
93.31 11.40% |
912.08 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
4581 Tamiami Trail North, Naples, FL, United States, 34103
646 491 9132
6
| Name | Title | Year Born |
|---|---|---|
| Dr. David Joszef Tapolczay | CEO & Director | 1959 |
| Mr. Adam Sragovicz | Chief Financial Officer | 1970 |
| Dr. Joanne M. Holland | Chief Scientific Officer | 1975 |
| Mr. James Bligh | Interim CFO & Director | 1988 |
| Mr. Bill Begien | Senior VP of Investor Relations | NA |
| Dr. Andrew Regan | Founder, CEO & Director | 1967 |
| Mr. James Bligh | Co-Founder, CFO & Director | 1988 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.64%
Communication Services
-0.16%
Consumer Cyclical
-0.15%
Consumer Defensive
+0.32%
Energy
-0.06%
Financial Services
-0.57%
Financials
+2.59%
Healthcare
-1.23%
Industrials
-0.83%
Real Estate
-0.24%
Technology
-2.67%
Utilities
-0.22%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...